Cozart, the Aim-listed company that provides the police with its RapiScan testing kits to detect crack, heroin and cocaine in saliva, is confident of sales opportunities for its devices in the workplace and for use on drivers in Britain and on the Continent. Sales for the six months to 30 November rose 31% to £2.5m, more than doubling pretax profits to £196,000. The shares added 2½p to 41½p.